200 related articles for article (PubMed ID: 33288848)
61. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
62. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
Rinaldi A; Mensah AA; Kwee I; Forconi F; Orlandi EM; Lucioni M; Gattei V; Marasca R; Berger F; Cogliatti S; Cavalli F; Zucca E; Gaidano G; Rossi D; Bertoni F
Br J Haematol; 2013 Oct; 163(2):194-204. PubMed ID: 23961875
[TBL] [Abstract][Full Text] [Related]
63. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
64. ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma.
Xie W; Wu M; Fu T; Li X; Wang Z; Hu Y; Zhu L; Zhang G
Gene; 2017 Sep; 627():255-262. PubMed ID: 28629825
[TBL] [Abstract][Full Text] [Related]
65. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
66. Increased expression of the spindle checkpoint protein BubR1 is associated with high cell proliferation in primary gastrointestinal diffuse large B cell lymphoma.
Chen F; Yang G; Xia B
Cell Biochem Biophys; 2013 Jul; 66(3):747-52. PubMed ID: 23400934
[TBL] [Abstract][Full Text] [Related]
67. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.
Matthews JM; Bhatt S; Patricelli MP; Nomanbhoy TK; Jiang X; Natkunam Y; Gentles AJ; Martinez E; Zhu D; Chapman JR; Cortizas E; Shyam R; Chinichian S; Advani R; Tan L; Zhang J; Choi HG; Tibshirani R; Buhrlage SJ; Gratzinger D; Verdun R; Gray NS; Lossos IS
Blood; 2016 Jul; 128(2):239-48. PubMed ID: 27151888
[TBL] [Abstract][Full Text] [Related]
68. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
69. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
[TBL] [Abstract][Full Text] [Related]
70. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
71. Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression.
You JS; Kang JK; Seo DW; Park JH; Park JW; Lee JC; Jeon YJ; Cho EJ; Han JW
Cancer Res; 2009 Jul; 69(14):5716-25. PubMed ID: 19567677
[TBL] [Abstract][Full Text] [Related]
72. FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma.
Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Jan; 8(2):2466-2476. PubMed ID: 27911272
[TBL] [Abstract][Full Text] [Related]
73. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
74. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
75. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
76. The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; De Raeve H; De Smedt E; Vlummens P; Szablewski V; Devin J; Faict S; De Veirman K; Menu E; Offner F; Spaargaren M; Moreaux J; Vanderkerken K; Van Valckenborgh E; De Bruyne E
Br J Cancer; 2019 Jun; 120(12):1137-1146. PubMed ID: 31089208
[TBL] [Abstract][Full Text] [Related]
77. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
[TBL] [Abstract][Full Text] [Related]
78. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
79. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
80. High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.
Zhang Y; You X; Liu H; Xu M; Dang Q; Yang L; Huang J; Shi W
Ann Hematol; 2017 Sep; 96(9):1485-1491. PubMed ID: 28616658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
